Literature DB >> 30328084

Association of Cytotoxic T-Lymphocyte Antigen-4 (CTLA4) Gene and CD80 Expression in Children with Idiopathic Nephrotic Syndrome.

Amarjeet Mehta1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30328084     DOI： 10.1007/s12098-018-2803-0

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  6 in total

1.  Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.

Authors:  Eduardo H Garin; Wei Mu; John M Arthur; Christopher J Rivard; Carlos E Araya; Michiko Shimada; Richard J Johnson
Journal:  Kidney Int       Date:  2010-05-19       Impact factor: 10.612

2.  CTLA4 polymorphisms in minimal change nephrotic syndrome in children: a case-control study.

Authors:  Kim Ohl; Christiane Eberhardt; Clemens Spink; Katharina Zahn; Norbert Wagner; Thomas Eggermann; Markus J Kemper; Uwe Querfeld; Bernd Hoppe; Sigrid Harendza; Klaus Tenbrock
Journal:  Am J Kidney Dis       Date:  2014-03-20       Impact factor: 8.860

3.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

4.  Cytotoxic T- Lymphocyte Antigen-4 (CTLA4) Gene Expression and Urinary CTLA4 Levels in Idiopathic Nephrotic Syndrome.

Authors:  Om P Mishra; Prashant Chhabra; Gopeshwar Narayan; Pradeep Srivastava; Rajniti Prasad; Ankur Singh; Abhishek Abhinay; Vineeta V Batra
Journal:  Indian J Pediatr       Date:  2018-07-03       Impact factor: 1.967

5.  The CTLA-4 +49GG genotype is associated with susceptibility for nephrotic kidney diseases.

Authors:  Clemens Spink; Gesa Stege; Klaus Tenbrock; Sigrid Harendza
Journal:  Nephrol Dial Transplant       Date:  2013-08-23       Impact factor: 5.992

6.  CTLA-4: a negative regulator of autoimmune disease.

Authors:  N J Karandikar; C L Vanderlugt; T L Walunas; S D Miller; J A Bluestone
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.